Alnylam Will Seek Early Approval, But Givosiran Likely To Reach Market Later
Executive Summary
Alnylam reported interim Phase III results that it believes support a filing for accelerated approval and a rapid market entry, but a US FDA decision may be delayed by up to six months to allow for a bigger dataset and complete safety assessment in acute hepatic porphyria.
You may also be interested in...
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
The latest drug development news and highlights from our US FDA Performance Tracker.
Alnylam Ramps Up Commercial Planning For Givosiran Based On Phase III Data
The company expects to complete a rolling NDA submission for its second RNAi therapeutic in mid-2019, and sees an opportunity to target severe and more moderate patients with acute hepatic porphyria.
Keeping Track: Some Calm Before The Storm
The latest drug development news and highlights from our US FDA Performance Tracker.